Biontech Se Share Price Today
(NASDAQ: BNTX)

Name: Biontech Se Share Price Today (NASDAQ: BNTX) - Biontech Se Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Biontech Se share price is $90.29 & ₹7,723.59 as on 1 Apr 2025, 2.30 'hrs' IST

$90.29

▲

-0.77

(-0.85%)

Market is closed - opens 7 PM, 02 Apr 2025

View live Biontech Se share price in Dollar and Rupees. Guide to invest in Biontech Se stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Biontech Se, along with analyst recommendations, forecasts, and comprehensive financials.

Biontech Se share price movements

Today's Low: $87.92
Today's High: $92.39
$90.29
2.62%
Downside
Day's Volatility :4.84%
Upside
2.27%
52 Weeks Low: $76.53
52 Weeks High: $131.49
$90.29
15.24%
Downside
52 Weeks Volatility :41.8%
Upside
31.33%

Biontech Se (BNTX) Returns

Period	Biontech Se	Sector (Health Care)	Index (Russel 2000)
3 Months	-21.69%	4.2%	0.0%
6 Months	-24.13%	-6.3%	0.0%
1 Year	-1.35%	-0.6%	0.0%
3 Years	-51.52%	3.8%	-15.4%

Biontech Se (BNTX) Key Statistics

in dollars & INR

Previous Close	$91.06
Open	$92.27
Today's High	$92.39
Today's Low	$87.92
Market Capitalization	$22.8B
Today's Volume	$2.3M
52 Week High	$131.49
52 Week Low	$76.5301
Revenue TTM	$2.8B
EBITDA	$-1.0B
Earnings Per Share (EPS)	$-3.01
Profit Margin	-24.18%
Quarterly Earnings Growth YOY	-0.43%
Return On Equity TTM	-3.36%

How to invest in Biontech Se Stock (BNTX) from India?

It is very easy for Indian residents to invest directly in Biontech Se from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Biontech Se stock in both Indian Rupees (INR) and US Dollars (USD). Search for Biontech Se or BNTX on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Biontech Se or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Biontech Se shares which would translate to 0.009 fractional shares of Biontech Se as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Biontech Se, in just a few clicks!

Returns in Biontech Se (BNTX) for Indian investors in Rupees

The Biontech Se stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Biontech Se investment value today

Current value as on today

₹1,01,285

Returns

₹1,285

(+1.28%)

Returns from Biontech Se Stock

₹1,355 (-1.35%)

Dollar Returns

₹2,640 (+2.64%)

Indian investors sentiment towards Biontech Se (BNTX)

-42%

Period: Mar 2, 2025 to Apr 1, 2025. Change in 30 Days versus previous period

Search interest for Biontech Se Stock from India on INDmoney has decreased by -42% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Biontech Se

Baillie Gifford & Co Limited.
3.43%
FMR Inc
3.21%
Flossbach von Storch AG
1.84%
PRIMECAP Management Company
1.79%
Pfizer Inc
1.52%
BlackRock Inc
0.77%

Analyst Recommendation on Biontech Se

Buy

54%Buy

37%Hold

8%Sell

Based on 24 Wall street analysts offering stock ratings for Biontech Se(by analysts ranked 0 to 5 stars)

Based on 24 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Biontech Se Stock (BNTX)

What analysts predicted

Upside of 53.02%

Target:

$138.16

Current:

$90.29

Insights on Biontech Se Stock (Ticker Symbol: BNTX)

Price Movement
In the last 1 month, BNTX stock has moved down by -20.0%
Decreasing Revenue
BioNTech SE has seen a decline in its revenue over the last two quarters. The revenue decreased from $1.22 billion to $1.19 billion, reflecting an average decrease of 3.1% per quarter.
Increasing Net Profit
BioNTech SE has shown a strong improvement in its net profit over the last three quarters. The net profit increased significantly from a loss of $811.88 million to a profit of $259.5 million. On average, the profit has grown by 270% each quarter, indicating a positive trend in the company's financial performance.
BNTX vs ONC (1 yr)
In the last 1 year, Beone Medicines Ltd has given 76.9% return, outperforming this stock by 78.3%
BNTX vs VRTX (3 yr)
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 37.5% return, outperforming this stock by 87.0%
Price to Sales
Biontech SE has a Price-to-Sales (P/S) Ratio of 7.9, meaning that investors are willing to pay $7.9 for every $1 of sales made by the company. In comparison, Beone Medicines Ltd has a slightly lower P/S Ratio of 7.5, indicating that investors are paying $7.5 for every $1 of sales. This suggests that investors value Biontech SE's sales more highly than those of Beone Medicines Ltd.

BNTX Biontech Se Financials in INR & Dollars

	FY19	Y/Y Change
Revenue	$120.7M	↓ 14.88%
Net Income	$-199.1M	↑ 273.13%
Net Profit Margin	-165.0%	↓ 127.36%

	FY20	Y/Y Change
Revenue	$586.7M	↑ 344.17%
Net Income	$18.5M	↓ 108.48%
Net Profit Margin	3.15%	↑ 168.15%

	FY21	Y/Y Change
Revenue	$21.5B	↑ 3834.42%
Net Income	$11.6B	↑ 67613.82%
Net Profit Margin	54.24%	↑ 51.09%

	FY22	Y/Y Change
Revenue	$18.3B	↓ 8.78%
Net Income	$10.0B	↓ 8.34%
Net Profit Margin	54.5%	↑ 0.26%

	FY23	Y/Y Change
Revenue	$4.2B	↓ 77.94%
Net Income	$1.0B	↓ 90.14%
Net Profit Margin	24.36%	↓ 30.14%

	FY24	Y/Y Change
Revenue	$2.8B	↓ 27.96%
Net Income	$-665.3M	↓ 171.51%
Net Profit Margin	-24.18%	↓ 48.54%

	Q3 FY23	Q/Q Change
Revenue	$1.6B	↑ 65.2%
Net Income	$488.8M	↑ 185.12%
Net Profit Margin	30.96%	↑ 13.02%

	Q4 FY23	Q/Q Change
Revenue	$1.6B	↑ 0.0%
Net Income	$499.5M	↑ 0.0%
Net Profit Margin	30.96%	↑ 0.0%

	Q1 FY24	Q/Q Change
Revenue	$205.1M	↓ 87.24%
Net Income	$-344.5M	↓ 169.22%
Net Profit Margin	-167.96%	↓ 198.92%

	Q2 FY24	Q/Q Change
Revenue	$139.2M	↓ 31.45%
Net Income	$-873.6M	↑ 156.15%
Net Profit Margin	-627.66%	↓ 459.7%

	Q3 FY24	Q/Q Change
Revenue	$1.2B	↑ 849.5%
Net Income	$195.5M	↓ 124.07%
Net Profit Margin	15.91%	↑ 643.57%

	Q4 FY24	Q/Q Change
Revenue	$1.2B	↓ 3.11%
Net Income	$259.5M	↑ 32.77%
Net Profit Margin	21.81%	↑ 5.9%

	FY19	Y/Y Change
Profit	$-150.3M	↑ 363.86%

	FY20	Y/Y Change
Profit	$-270.1M	↑ 64.18%

	FY21	Y/Y Change
Profit	$17.1B	↓ 6907.87%

	FY22	Y/Y Change
Profit	$13.5B	↓ 15.46%

	FY23	Y/Y Change
Profit	$3.5B	↓ 74.81%

	FY24	Y/Y Change
Profit	$2.2B	↓ 31.36%

	Q3 FY23	Q/Q Change
Profit	$1.4B	↑ 451.74%

	Q4 FY23	Q/Q Change
Profit	$1.4B	↑ 0.0%

	Q1 FY24	Q/Q Change
Profit	$140.5M	↓ 90.06%

	Q2 FY24	Q/Q Change
Profit	$74.5M	↓ 46.43%

	Q3 FY24	Q/Q Change
Profit	$1.1B	↑ 1418.69%

	Q4 FY24	Q/Q Change
Profit	$946.5M	↓ 10.0%

	FY19	Y/Y Change
Operating Cash Flow	$-220.6M	↑ 241.25%
Investing Cash Flow	$-85.7M	↑ 16.05%
Financing Cash Flow	$425.9M	↑ 4.96%

	FY20	Y/Y Change
Operating Cash Flow	$-16.4M	↓ 93.21%
Investing Cash Flow	$-176.2M	↑ 87.83%
Financing Cash Flow	$1.1B	↑ 133.43%

	FY21	Y/Y Change
Operating Cash Flow	$1.0B	↓ 6703.09%
Investing Cash Flow	$-640.0M	↑ 290.82%
Financing Cash Flow	$106.5M	↓ 89.47%

	Q3 FY23	Q/Q Change
Operating Cash Flow	$908.4M	↑ 4.89%
Investing Cash Flow	$-1.3B	↑ 0.0%
Financing Cash Flow	$-13.8M	↓ 95.85%

Biontech Se Technicals Summary

Sell

Neutral

Buy

Biontech Se is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Biontech Se (BNTX) Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Biontech Se	-19.07%	-24.13%	-1.35%	-51.52%	71.17%
Alnylam Pharmaceuticals, Inc.	10.88%	-5.81%	69.33%	58.1%	141.69%
Regeneron Pharmaceuticals, Inc.	-7.39%	-40.69%	-35.37%	-11.66%	25.07%
Beone Medicines Ltd	10.85%	16.03%	76.86%	25.45%	93.63%
Vertex Pharmaceuticals Incorporated	0.31%	4.89%	18.4%	80.44%	103.41%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Biontech Se	160.8	NA	0.04	-4.91	-0.03	-0.04	NA	80.89
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	0.82	-15.01	-0.03	NA	0.52
Regeneron Pharmaceuticals, Inc.	16.53	16.53	0.95	42.58	0.16	0.07	0.01	273.57
Beone Medicines Ltd	NA	NA	NA	1.45	-0.19	-0.06	NA	31.22
Vertex Pharmaceuticals Incorporated	32.84	NA	1.4	18.04	-0.03	0.13	NA	63.87

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Biontech Se	Buy	$22.8B	71.17%	160.8	-24.18%
Alnylam Pharmaceuticals, Inc.	Buy	$34.9B	141.69%	NA	-12.37%
Regeneron Pharmaceuticals, Inc.	Buy	$69.7B	25.07%	16.53	31.07%
Beone Medicines Ltd	NA	$30.1B	93.63%	NA	-16.92%
Vertex Pharmaceuticals Incorporated	Buy	$126.5B	103.41%	32.84	-4.86%

Biontech Se Dividend announcements

Biontech Se Dividends June, 2022
In the quarter ending June,2022. Biontech Se has declared dividend of $2.11

About Biontech Se

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in phase 1 clinical trial for solid tumors; and BNT122/RO7198457, which is in Phase 2 clinical trial to treat adjuvant high-risk muscle-invasive urothelial carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, advance melanoma, as well as in phase 1a/1b clinical trial for advanced/metastatic solid tumors. It also develops BNT211, which is in phase 1 clinical trial to treat CLDN6+ solid tumors; BNT221, phase 1 clinical trial for the treatment of cancer; BNT311/GEN1046 (acasunlimab), which is in phase 3 clinical trial for solid tumors; BNT312/GEN1042, which is in phase 1/2 and 1 clinical trial to treat solid tumors; BNT314/GEN1059, which is in Phase 1/2 clinical trial for advanced or metastatic solid tumors; BNT315/GEN1055, which is in phase 1/2 clinical trial for advanced solid tumors; BNT317, which is in phase 1 clinical trial for advanced solid tumors; BNT327, which is in phase 1/2, 2, and 3 clinical trial to treat small cell lung cancer, advanced/metastatic tnbc, neuroendocrine neoplasm, malignant mesothelioma, EGFR-mutant non-squamous, hepatocellular carcinoma, and advanced solid tumors; and BNT316/ONC-392, which is in phase 1/2, 2, and 3 clinical trial to treat metastatic, non-small cell lung cancer, platinum-resistant ovarian cancer, metastatic castration resistant prostate cancer, and advanced or metastatic solid tumor. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

Organization	Biontech Se
Employees	6772
CEO	Dr. Ugur Sahin M.D.
Industry	Health Technology

Management People of Biontech Se

Name	Title
Dr. Ugur Sahin M.D.	Co-Founder, CEO & Chair of the Management Board
Dr. Ozlem Tureci M.D.	Co-Founder, Chief Medical Officer & Member of Management Board
Mr. Jens H. Holstein	CFO & Member of Management Board
Dr. Sierk Poetting Ph.D.	MD, COO & Member of Management Board
Mr. Ryan Richardson	Chief Strategy Officer, MD & Member of Management Board
Dr. James Timothy Patrick Ryan Ph.D.	Chief Legal & Business Officer & Member of the Management Board
Ms. Annemarie Hanekamp	Chief Commercial Officer & Member of Management Board
Ms. Lisa Birringer	Senior Vice President of Global Financial Reporting & Accounting
Mr. Zach Taylor	Senior Vice President of Corporate Development & Strategy
Ms. Beate Berns	Senior Vice President of Global Human Resources

Important FAQs about investing in BNTX Stock from India :

What is Biontech Se share price today?

Biontech Se share price today stands at $90.29, Open: $92.27 ; Previous Close: $91.06 ; High: $92.39 ; Low: $87.92 ; 52 Week High: $131.49 ; 52 Week Low: $76.53.

The stock opens at $92.27, after a previous close of $91.06. The stock reached a daily high of $92.39 and a low of $87.92, with a 52-week high of $131.49 and a 52-week low of $76.53.

Can Indians buy Biontech Se shares?

Yes, Indians can invest in the Biontech Se (BNTX) from India.

With INDmoney, you can buy Biontech Se at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Biontech Se at zero transaction cost.

How can I buy Biontech Se shares from India?

It is very easy to buy Biontech Se from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Biontech Se (BNTX) be purchased?

Yes, you can buy fractional shares of Biontech Se with INDmoney app.

What are the documents required to start investing in Biontech Se stocks?

To start investing in Biontech Se, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.